# **RESEARCH HIGHLIGHT**

**Open Access** 

# Biomaterials barcoding: a high-throughput breakthrough



Masoud Mozafari<sup>1\*</sup>

## Highlights

In the world of biomedical breakthroughs, Rice University bioengineer Omid Veiseh and his team are making waves with their recent publication in Nature Biomedical Engineering (2023) (Mukherjeeet al., Nat Biomed Eng. 7:867–886, 2023). This study is a pivotal step in our fight against fibrosis, an issue that has long hindered medical progress. Their pioneering research isn't just a scientific milestone; it's a game-changer in how we tackle tissue scarring. Veiseh and his team have introduced an innovative method that allows for rapid testing of various materials within living organisms. By employing cellular barcoding and cutting-edge sequencing techniques, they've accelerated the assessment of multiple hydrogels. As we delve deeper into the specifics of this groundbreaking study, we uncover not just scientific insights, but the potential to revolutionize how we conceptualize and utilize biomaterials. This discussion isn't merely about research methods; it's about the ray of hope and boundless opportunities this study illuminates across the spectrum of biomaterials science.

Implanted devices often trigger a complex host immune response, leading to inflammation, cellular deposition, and ultimately fibrotic overgrowth. This process is a significant hurdle in the development of biomaterials with improved biocompatibility. Among the extensively studied biomaterials, alginate-based hydrogels have found applications in various fields. Alginate-based hydrogels are a well-established biomaterial due to their biocompatibility, mild gelation conditions, and ease of modification, making them attractive for various biomedical applications [1]. However, these hydrogels also face host immune recognition challenges, especially when encapsulating donor tissue [2]. To address this challenge, various approaches, such as chemical modification and adjustments to implant geometry, have been explored [3]. The study by Mukherjee et al. represents a significant

\*Correspondence:

Masoud Mozafari

mozafari.masoud@gmail.com

onwersity of ould, ould, finiand

step forward in tackling this issue through high-throughput screening.

Traditional in vivo biomaterial screening methods have limitations, often involving one animal or implantation site for a single biomaterial. Mukherjee and colleagues propose a novel approach that employs cellular barcoding to screen multiple hydrogel formulations within a single host. This approach eliminates the need for an extensive number of animals and substantially increases the throughput of biomaterial screening. To achieve this, they encapsulate distinct barcoding cells within hydrogel capsules made from new alginate analogues. These barcoding cells, each representing a unique biomaterial, are human umbilical vein endothelial cells (HUVECs) with distinct genetic profiles, identified through single nucleotide polymorphisms (SNPs) via next-generation sequencing. The cellular barcoding technique enables the researchers to screen up to 20 distinct biomaterials in a single mouse and over 100 biomaterials in a nonhuman primate, representing a remarkable increase in throughput. Moreover, a dual-donor barcoding strategy was introduced to expand the library to 400 different codes, allowing even greater biomaterial screening throughput. This innovative approach has the potential



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

<sup>&</sup>lt;sup>1</sup> Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland

to revolutionize the way we identify biomaterials with antifibrotic properties, streamlining the process and minimizing the number of living subjects required [4]. This strategy represents a pivotal step forward in research methodologies, aligning scientific progress with ethical considerations by ensuring rigorous testing while minimizing the impact on animal subjects.

The study not only demonstrates the effectiveness of this high-throughput screening method but also showcases the practical applications of the identified lead hydrogel formulations (Fig. 1). One of the lead formulations, Z4-A10, was applied to encapsulate xenogeneic human pancreatic islets, resulting in long-term glycaemic control in a pro-fibrotic mouse model. This breakthrough has promising implications for the field of diabetes therapy, offering an alternative to immunosuppressive drugs. Additionally, two other lead hydrogels, Z1-A3 and B2-A17, were used to coat medical-grade catheters, preventing fibrotic overgrowth and enhancing their biocompatibility. This work highlights the potential of these hydrogels for improving the long-term performance of medical devices and therapeutic cell encapsulation. The study delves further into the structural features of the lead small molecules, shedding light on commonalities among the top-performing hydrogels. Hydrophilic PEG linkers, a hydrophilic surface, and the presence of certain structural motifs were found to be associated with improved antifibrotic properties. This structural insight offers guidance for future material design, potentially opening avenues for the development of new antifibrotic hydrogel formulations [6].

While the study represents a significant advancement in biomaterial screening, it also has its limitations. Crossspecies genetic homology between humans and primates can pose challenges in differentiating genetic signals, and additional work is required to refine species distinction. Furthermore, enhancing DNA output from highly fibrosed capsules is essential for the comprehensive identification of biomaterials. The long-term stability, toxicity, and biocompatibility of lead small molecules also need further investigation [7]. In evaluating the biomaterials barcoding technology, it's pivotal to assess its feasibility,



**Fig. 1** High-Throughput Biomaterial Screening Enabled by Cell Barcoding. It is showcasing the innovative high-throughput in vivo screening method employing cellular barcoding and next-generation sequencing. The figure depicts the barcoding technique, exhibiting the encapsulation of distinct barcoding cells within hydrogel capsules in mice and non-human primates. It visualizes the high throughput of material screening, the structural insights into lead hydrogels, functional outcomes in encapsulating pancreatic islets, and coated catheters, emphasizing their potential applications. The figure also hints at future directions in refining species distinction, exploring long-term stability, toxicity, and advancing biomaterial screening methods. (Reprinted with permission from [5])

reliability, safety, and economic implications to understand its practicality and widespread implementation. The feasibility of this high-throughput platform lies in its ability to efficiently screen numerous biomaterials within a single living subject, significantly reducing the number of required animals and time. Moreover, ensuring the reliability of barcoding techniques and sequencing methodologies is crucial to ascertain accurate identification and characterization of biomaterials. Safety considerations encompass the host response to the barcoded biomaterials, emphasizing biocompatibility and the absence of adverse effects, ensuring the translated clinical applicability. Addressing the economic aspects involves assessing the cost-effectiveness and scalability of the technology, considering the expenses associated with next-gen sequencing, cell barcoding, and data analysis. Comprehensive evaluation across these domains will provide an encompassing understanding of the viability and potential challenges of implementing biomaterials barcoding platforms in biomedical research and clinical applications.

In summary, Mukherjee et al.'s pioneering study marks a new era in the field of biomaterials research, particularly in combating fibrosis. By introducing a highthroughput in vivo screening method using cellular barcoding and next-generation sequencing, they have not only expanded the throughput of material screening but have also identified promising lead hydrogel formulations with antifibrotic properties. These lead hydrogels hold significant promise in improving the biocompatibility and long-term performance of medical devices and therapeutic cell encapsulation. With potential applications in diabetes therapy and medical device coatings, this research has the potential to benefit millions of patients worldwide. It exemplifies the power of innovative thinking and interdisciplinary collaboration in addressing complex biomedical challenges.

#### Acknowledgements

Not applicable.

#### Author's contributions

This highlights research article, authored by Masoud Mozafari, entails a review of the seminal research conducted by Mukherjee et al. The content presented in this summary, analyzing the research titled 'Screening hydrogels for antifibrotic properties by implanting cellularly barcoded alginates in mice and a non-human primate' and published in Nature Biomedical Engineering, reflects the sole effort of Masoud Mozafari in summarizing, critically assessing, and presenting the key findings, implications, and significance of the original research article. Mozafari's contribution lies in the thorough interpretation and presentation of the research conducted by Mukherjee et al. The author has read and approved the final manuscript.

### Funding

There is no funding to support this article.

## Availability of data and materials

Not applicable.

## Declarations

## Ethics approval and consent to participate

Not applicable

## **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

Received: 18 October 2023 Accepted: 4 December 2023 Published online: 02 January 2024

#### References

- Teng K, An Q, Chen Y, Zhang Y, Zhao Y. Recent development of alginatebased materials and their versatile functions in biomedicine, flexible electronics, and environmental uses. ACS Biomater Sci Eng. 2021;7(4):1302– 37. https://doi.org/10.1021/acsbiomaterials.1c00116.
- Rahmati M, Mozafari M. Protein adsorption on polymers. Mater Today Commun. 2018;17:527–40. https://doi.org/10.1016/j.mtcomm.2018.10. 024.
- Kargozar S, Ramakrishna S, Mozafari M. Chemistry of biomaterials: future prospects. Curr Opinion Biomed Eng. 2019;10:181–90. https://doi.org/10. 1016/j.cobme.2019.07.003.
- Nash A, Lokhorst N, Veiseh O. Localized immunomodulation technologies to enable cellular and organoid transplantation. Trends Mol Med. 2023;29:635–45. https://doi.org/10.1016/j.molmed.2023.05.008.
- Mukherjee S, Kim B, Cheng LY, Doerfert MD, Li J, Hernandez A, et al. Screening hydrogels for antifibrotic properties by implanting cellularly barcoded alginates in mice and a non human primate. Nat Biomed Eng. 2023;7:867–86. https://doi.org/10.1038/s41551-023-01016-2.
- Josyula A, Parikh KS, Pitha I, Ensign LM. Engineering biomaterials to prevent post-operative infection and fibrosis. Drug Del Transl Res. 2021;11:1675–88. https://doi.org/10.1007/s13346-021-00955-0.
- Wolf MT, Dearth CL, Ranallo CA, LoPresti ST, Carey LE, Daly KA, et al. Macrophage polarization in response to ECM coated polypropylene mesh. Biomaterials. 2014;35:6838–49. https://doi.org/10.1016/j.biomaterials. 2014.04.115.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.